BioScrip Inc. (NASDAQ:BIOS)’s share price was up 3% during mid-day trading on Tuesday . The company traded as high as $2.77 and last traded at $2.73, with a volume of 473,162 shares traded. The stock had previously closed at $2.65.

Separately, Zacks Investment Research upgraded shares of BioScrip from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research report on Monday, July 11th.

The company’s market capitalization is $188.46 million. The stock has a 50-day moving average price of $2.62 and a 200-day moving average price of $2.36.

BioScrip (NASDAQ:BIOS) last issued its earnings results on Monday, August 8th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.05. The business had revenue of $232.50 million for the quarter, compared to analysts’ expectations of $229.58 million. BioScrip’s revenue for the quarter was down 11.4% on a year-over-year basis. On average, equities analysts anticipate that BioScrip Inc. will post ($0.20) earnings per share for the current year.

In other BioScrip news, Director David W. Golding bought 12,500 shares of the business’s stock in a transaction on Friday, June 17th. The stock was purchased at an average price of $2.48 per share, for a total transaction of $31,000.00. Following the completion of the transaction, the director now directly owns 42,500 shares of the company’s stock, valued at $105,400. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Coliseum Capital Management, L bought 4,200,000 shares of the business’s stock in a transaction on Wednesday, June 22nd. The shares were acquired at an average price of $2.00 per share, with a total value of $8,400,000.00. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in BioScrip stock. Diamond Hill Capital Management Inc. raised its position in BioScrip Inc. (NASDAQ:BIOS) by 2.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,055,476 shares of the company’s stock after buying an additional 74,757 shares during the period. Diamond Hill Capital Management Inc. owned 4.44% of BioScrip worth $5,347,000 as of its most recent SEC filing.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.